Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Delcath Systems Sees 2025 CHEMOSAT And HEPZATO KIT Revenue Climbing To $94M–$98M In 2025, Up Over 150% YoY, Sees 83%–85% Gross Margins

Author: Benzinga Newsdesk | May 22, 2025 06:08am
  • 2025 Full Year Total Revenue Guidance of $94 to $98 million
  • Delcath Announces Plan to Enter into National Medicaid Drug Rebate Agreement

Posted In: DCTH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist